Edition:
United Kingdom

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

32.15USD
23 Feb 2018
Change (% chg)

$-0.46 (-1.41%)
Prev Close
$32.61
Open
$32.60
Day's High
$32.77
Day's Low
$30.76
Volume
235,462
Avg. Vol
144,049
52-wk High
$41.24
52-wk Low
$16.78

Select another date:

Thu, Feb 22 2018

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial

* LA JOLLA PHARMACEUTICAL CO - ESTABLISHED WHOLESALE ACQUISITION COST OF $1,500 PER VIAL FOR A 1 ML, SINGLE-DOSE, 2.5 MG/ML VIAL OF GIAPREZA Source text: (http://bit.ly/2nm3hfv) Further company coverage:

BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​

* BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​ Source text: (http://bit.ly/2D4NbRm) Further company coverage:

BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018

* LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2BTfmOK) Further company coverage:

FDA approves La Jolla's low blood pressure drug

La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

FDA approves La Jolla's low blood pressure drug

Dec 21 La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

BRIEF-La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure

* U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE

BRIEF-La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401

* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

Select another date: